valerates has been researched along with Carcinoma 256, Walker in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonatto, SJ; Brito, GA; Fernandes, LC; Kryczyk, M; Kuczera, D; Mund, RC; Nunes, EA; Tanhoffer, RA; Yamazaki, RK | 1 |
| Alves, L; Coelho, I; de Lima, C; Donatti, L; Fernandes, LC; Fonseca Guimarães, Fde S; Kuczera, D; Machado, AF; Naliwaiko, K; Nunes, EA; Paro de Oliveira, HH; Yamaguchi, A | 1 |
2 other study(ies) available for valerates and Carcinoma 256, Walker
| Article | Year |
|---|---|
Beta-hydroxy-beta-methylbutyrate supplementation reduces tumor growth and tumor cell proliferation ex vivo and prevents cachexia in Walker 256 tumor-bearing rats by modifying nuclear factor-kappaB expression.
Topics: Animals; Cachexia; Carcinoma 256, Walker; Cell Division; Glycogen; Liver; Male; Muscle, Skeletal; NF-kappa B; Rats; Rats, Wistar; Valerates | 2008 |
Bax/Bcl-2 protein expression ratio and leukocyte function are related to reduction of Walker-256 tumor growth after β-hydroxy-β-methylbutyrate (HMB) administration in Wistar rats.
Topics: Animals; Antineoplastic Agents; bcl-2-Associated X Protein; Carcinoma 256, Walker; Cell Proliferation; Male; Microscopy, Electron, Transmission; Neoplasm Transplantation; Neutrophils; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Wistar; Valerates | 2012 |